Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Francis Steltz on Jul 24th, 2026

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $81.60.

A number of research firms have commented on HALO. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd.

Check Out Our Latest Research Report on Halozyme Therapeutics

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the sale, the director owned 42,044 shares of the company’s stock, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HALO. Larson Financial Group LLC raised its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. Measured Wealth Private Client Group LLC boosted its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares in the last quarter. Clearstead Advisors LLC grew its holdings in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 331 shares during the period. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the third quarter worth $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $80.84 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company has a market capitalization of $9.59 billion, a P/E ratio of 29.08, a PEG ratio of 0.32 and a beta of 0.84. The business has a 50 day simple moving average of $72.79 and a 200-day simple moving average of $70.50. Halozyme Therapeutics has a twelve month low of $57.67 and a twelve month high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts anticipate that Halozyme Therapeutics will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.